Novartis Femara
Executive Summary
The oncologics committee will meet Dec. 13 at 8:30 a.m. to review letrozole 2.5 mg tablets as first-line therapy in postmenopausal women with advanced breast cancer
The oncologics committee will meet Dec. 13 at 8:30 a.m. to review letrozole 2.5 mg tablets as first-line therapy in postmenopausal women with advanced breast cancer. |